A Systematic Review and Meta-Analysis: The Long-Term Effects of Oral N-Acetylcysteine in Chronic Obstructive Pulmonary Disease
DOI:
https://doi.org/10.11594/nstp.2024.4404Keywords:
N-Acetylcysteine (NAC), chronic obstructive pulmonary disease (COPD), exacerbationAbstract
Chronic obstructive pulmonary disease (COPD) is one of the world's most prevalent causes of morbidity and mortality. About 5.6% of Indonesians have COPD. Most COPD patients have mucus hypersecretion and inadequate mucus clearance, leading to airway obstruction. N-acetylcysteine (NAC) is a mucolytic drug with antioxidant and anti-inflammatory effects. Long-term oral NAC use in COPD remains controversial. We searched four databases to analyze the effects of oral NAC in COPD over a minimum six-month treatment. The data was analyzed through Review Manager 5.4. Eight randomized controlled trials, comprising 3.187 patients, were selected for inclusion in the study. NAC had a lower risk of exacerbations (RR 0.78, 95% CI 0.66-0.93; p=0.005), whether at high dose (1200mg/day) or low dose (600mg/day). The risk is higher at the high dose (RR 0.90, p=0.04) than at the low dose (RR 0.70, p=0.0002). NAC did not affect FEV1 (mean difference 4.71, 95% CI -3.20-12.61; p=0.24), and adverse events were the same as with placebo (RR 1.14, 95% CI 0.78-1.67; p=0.51). Long-term oral NAC reduces the risk of COPD exacerbations at any dose and was well tolerated.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Nova Nasikhatussoraya, Hamid Faqih Umam, Ainingtyas Marda Rizkani, Hidayat Santoso
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this proceedings agree to the following terms:
Authors retain copyright and grant the Nusantara Science and Technology Proceedings right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this proceeding.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the proceedings published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this proceeding.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See the Effect of Open Access).
